A total of 69 Mergers & Acquisitions (M&A) deals (pending and completed) were announced in the Pharmaceuticals of United States, in the last twelve months resulting in a total deal value of over $85,048.7 million. In the LTM period, May 2022 turned out to be the most prolific in terms of deal size, with a total deal value of $15,853.4 million, resulting in an average deal value of $2,642.2 million during that month. On the other hand, the month of November 2021 was the most prolific in terms of deal volume, recording a total of 8 deals, resulting in an average deal value of $603.3 million during that month.
Of the 69 deals, the deal secured between Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd, was the largest M&A deal in the United States Pharmaceuticals sector, which was valued at $12,210.5 million and was completed on May 10, 2022. The second-largest deal was between Merck & Co Inc and Acceleron Pharma Inc, while the third-largest deal was between Danaher Corp and Aldevron LLC. The Merck & Co Inc-Acceleron Pharma Inc deal and the Danaher Corp-Aldevron LLC deal were valued at $11,500.0 million and $9,600.0 million, respectively. The fourth-largest deal was between Pfizer Inc-Arena Pharmaceuticals Inc valued at $6,700.0 million, whereas the deal between PerkinElmer Inc-Biolegend Inc valued at $5,250.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $45,260.5 million and accounted for nearly 53.22% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
United Kingdom
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward